Drug & intervention

mesna

RxCUI 44

Clinical trials17
Recruiting2
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…
Background context

Mesna

Mesna, sold under the brand name Mesnex among others, is a medication used in those taking cyclophosphamide or ifosfamide to decrease the risk of bleeding from the bladder. It is used either by mouth or injection into a vein. Common side effects include headache, vomiting, sleepiness, loss of appetite, cough, rash, and joint pain. Serious side effects include allergic reactions. Use during pregnancy appears to be safe for the baby but this use has not been well studied. Mesna is an organosulfur compound. It works by altering the breakdown products of cyclophosphamide and ifosfamide found in the urine making them less toxic. Mesna was approved for medical use in the United States in 1988. It is on the World Health Organization's List of Essential Medicines.

Read on Wikipedia ↗ Wikidata Q424997 ↗
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.

Clinical trials

17 shown
Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic MalignanciesNCT04959175 · 2021-09-23
RECRUITING
Autologous Stem Cell Transplantation in Patients With Systemic SclerosisNCT03630211 · 2018-07-31
RECRUITING
IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple SclerosisNCT06677710 · 2026-06-30
SUSPENDED
Cysteine-lowering Treatment With MesnaNCT04449536 · 2020-11-02
COMPLETED
Maximizing Outcome of Multiple Sclerosis TransplantationNCT03342638 · 2017-11-08
TERMINATED
Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) ReleaseNCT01205503 · 2010-09-01
COMPLETED
A Study of Pre-Operative Treatment of Newly-Diagnosed, Surgically-Resectable Osteosarcoma With Doxorubicin, Ifosfamide, Etoposide, and Cisplatin With Early Metabolic Assessment of ResponseNCT01258634 · 2010-07-01
TERMINATED
Vaccine and Chemotherapy for Previously Untreated Metastatic Breast CancerNCT00048893 · 2002-11-01
TERMINATED
High Dose Chemo/Radiotherapy and Hematopoietic Stem Cell Transplant for Patients With Multiple SclerosisNCT00040482 · 1999-04-01
COMPLETED
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast CancerNCT00003042 · 1997-05-30
COMPLETED
Combination Chemotherapy in Treating Patients With Metastatic Breast CancerNCT00006260 · 1997-05-01
COMPLETED
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Combination Chemotherapy in Treating Women With High-Risk Breast CancerNCT00002784 · 1996-06-01
COMPLETED
Combination Chemotherapy Followed by Radiation Therapy in Patients With Small Cell Lung CancerNCT00002822 · 1996-03-01
COMPLETED
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced CancerNCT00002854 · 1994-12-01
COMPLETED
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Patients With High-Risk Breast CancerNCT00002627 · 1994-11-01
UNKNOWN
Addition of Paclitaxel to High-Dose Combination Chemotherapy in Treating Women With Metastatic Breast CancerNCT00002628 · 1994-11-01
UNKNOWN
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Poor-Prognosis Breast CancerNCT00002509 · 1991-11-01
COMPLETED

Conditions being studied

Breast Cancer7Multiple Sclerosis2Autoimmune Diseases1Autoimmune Diseases of the Nervous System1Breast Neoplasms1Cancer1Demyelinating Autoimmune Diseases, Central Nervous System (CNS)1Demyelinating Diseases1Diffuse Sclerosis Systemic1Drug Effect1Hematologic Neoplasms1Immune System Diseases1Interstitial Lung Disease1Lung Cancer1Lung Metastases1Metastases, Neoplasm1Multiple Sclerosis, Relapsing-Remitting1Nervous System Diseases1Non-Active Secondary Progressive Multiple Sclerosis1Non-Active SPMS1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.